Lifestyle programs improve physical function in human trials, a change independent labs reproduce, while a trial reports increased mortality. Weight and systolic blood pressure reductions also recur across independent labs, though a trial shows no clear weight effect. Some authors work at Dong-A Pharmaceutical, LabCorp or Errekappa Euroterapici S.p.A.; a paper declares Pfizer ties.
124 findings in 58 papers from 2002 to 2026, 9 of them since April 2026
Independent labs found the same change in people. 46 independent labs in 18 countries; 1 trial, none about aging.
“Individuals randomized to ILI had lower odds of slow gait speed (<0.8 m/s) compared to those randomized to DSE (adjusted OR [95% CI]: 0.84 [0.71 to 0.99]).”
Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
120 peopleWomen40–42 yearsMidlife adults; perimenopausal women
International Journal of Drug Delivery Technology, Apr 11, 2026
What did studies of lifestyle modification program find?
78
Studies of lifestyle modification program measured 78 outcomes; the most studied are body weight (10 studies), physical function (5) and HbA1c (3).
Body weight
↓downin humans9↔no changein humans1
10 studies
Lifestyle modification program decreases body weight in humans (compared with control group) (-5.7 kg between-group).
“Significant between-group improvements were also observed in weight (-5.7 kg), BMI (-2.0 kg/m2), waist circumference (-6.3 cm), and HbA1c (-0.4%; all p < 0.001).”
Human trialcompared with control group6 monthsn = 181
Lifestyle modification program showed no clear effect on body weight in humans (overweight and obesity) (group difference = -0.17%; 95% CI = -1.04, 0.71; p = 0.71).
“Mean weight change (primary outcome) was -0.61% (95% confidence interval (CI) = -1.22, -0.01) in Lifestyle Africa and -0.44% (95% CI = -1.06, 0.18) in control with no significant difference”
Human trialoverweight and obesity7 to 9 monthsn = 494
Lifestyle modification program decreases body weight in humans (obese older adults, versus usual care) (3.22 ± 3.43 kg vs 0.03 ± 2.51 kg; 41.1% achieved 5% weight loss).
“Weight loss was statistically significant at the end of the intervention with a mean reduction of 0.03 ± 2.51 kg in the control group and 3.22 ± 3.43 kg in the intervention group (p < .001).”
Human trialobese older adults, versus usual care24 monthsn = 480
Lifestyle modification program improves physical function in humans (+25.5 m, 95%CI (3.2–47.9)).
“Physical performance measured by 6-minute walking test significantly increased by 12%, from 440 ± 62 m to 492 ± 73 m at six months in the intervention group, compared to 8% in the control group from 438 ± 93 m to 471 ± 66 m ( and: +25.5 m, 95%CI (3.2–47.9), p = 0.027).”
Lifestyle modification program decreases HbA1c in humans (type 2 diabetes) (7.9% (7.0-8.7) vs 8.6% (7.6-9.8), p<0.001).
“in the intervention vs standard-care group there was significantly lower median (interquartile range) HbA1c 7.9% (7.0-8.7) vs 8.6% (7.6-9.8), p<0.001”
Lifestyle modification program decreases HbA1c in humans.
“Among the analyzed blood markers, only HbA1c showed a statistically significant between-group difference (p = 0.043, ε2 = 0.01), and the effect size was interpreted as small.”
Lifestyle modification program decreases HbA1c in humans (mean difference = -0.24%, Hedges' g = 0.23).
“However, HbA1c did show differential change over time across conditions [time by condition interaction of F(1, 899) = 8.59, p = 0.004] with a Cohen’s d effect size of 0.21.”
Lifestyle modification program decreases HbA1c in humans (overweight and obesity) (mean difference = -0.24, 95% CI = -0.39, -0.09, p = 0.001).
“However, HbA1c was significantly lower at follow-up in Lifestyle Africa compared to the usual care group (mean difference = -0.24, 95% CI = -0.39, -0.09, p = 0.001).”
Human trialoverweight and obesity7 to 9 monthsn = 494
Lifestyle modification program decreases body mass index in humans (hospitalized psychiatric patients treated with antipsychotic and/or antidepressant drugs).
“significant reductions in BMI and FMI were observed among patients who completed the program”
Human trialhospitalized psychiatric patients treated with antipsychotic and/or antidepressant drugsn = 44
Lifestyle modification program showed no clear effect on physical activity in humans (inactive adults with obesity and elevated cardiovascular disease risk).
“We detected no changes in mean levels of physical activity, cardiometabolic risk factors or well-being.”
Human trialinactive adults with obesity and elevated cardiovascular disease risk6 months
Lifestyle modification program decreases menopausal symptoms in humans (perimenopausal women).
“By the fourth visit, a marked improvement was observed in the study group following the intervention; women reported mild or no symptoms across psychological, somatic, and urogenital domains.”
Human trialperimenopausal women6 monthsfemalesn = 120
World Family Medicine Journal/Middle East Journal of Family Medicine·
Cognitive function
↑upin humans1↔no changein humans1
2 studies
Lifestyle modification program improves cognitive function in humans (type 2 diabetes mellitus) (SMD = 1.66, 95% CI: 1.07 to 2.25).
“A meta-analysis revealed that the combined effect size of lifestyle interventions on global cognitive function improvement was significant (SMD = 1.66, 95% CI: 1.07 to 2.25, P < 0.001).”
Lifestyle modification program showed no clear effect on cognitive function in humans (without dementia) (g=-0.02; 95%CI [-0.14, 0.09]; p = .66).
“The pooled estimate comparing the effect of remote interventions versus comparators on cognition was not significant (g=-0.02; 95%CI [-0.14, 0.09]; p = .66)”
Lifestyle modification program decreases blood pressure in humans (residential wellness program).
“Finally, we have evaluated the impact of the wellness program on the blood pressure change, and a reduction was detected for both diastolic and systolic blood pressure.”
Human trialresidential wellness program10 daysn = 95
Lifestyle modification program improves blood pressure in humans (obese hypertensive patients).
“single or combined interventions based on telemedicine support, dietary modification, exercise, or peer support all helped obese hypertensive patients achieve weight loss and improve blood pressure control”
Lifestyle modification program showed no clear effect on body weight in humans (-0.17%, 95% CI -1.04, 0.71).
“The intent-to-treat analyses revealed the primary outcome of weight did not differentially change over time across conditions [time by condition interaction effect of F(1, 897) = 0.64, p = 0.42].”
Lifestyle modification program decreases body weight in humans (obese hypertensive patients).
“single or combined interventions based on telemedicine support, dietary modification, exercise, or peer support all helped obese hypertensive patients achieve weight loss”
Lifestyle modification program decreases blood glucose in humans (residential wellness program).
“At the end of the project, the glycemic value decreased in the whole group of participants: at the T1 moment, the glycemic value class was 0 for 72 volunteers (76%), 1 for 21 (22%) and 2 for 2 (3%).”
Human trialresidential wellness program10 daysn = 95
Lifestyle modification program showed no clear effect on cardiometabolic risk factors in humans (inactive adults with obesity and elevated cardiovascular disease risk).
“We detected no changes in mean levels of physical activity, cardiometabolic risk factors or well-being.”
Human trialinactive adults with obesity and elevated cardiovascular disease risk6 months
Lifestyle modification program improves metabolic syndrome Z-score in participants who did not increase cardiometabolic disease-related medications (mean change -1.6 ± SD 2.4).
“For the 11 participants who did not increase cardiometabolic disease‐related medications, MSSc significantly improved by a mean of −1.6 ± SD 2.4 compared to pre‐intervention values (P = 0.05; Figure ).”
Human trialin participants who did not increase cardiometabolic disease-related medications1.9 ± 0.5 yearsn = 11
Lifestyle modification program improves metabolic syndrome Z-score in humans (for participants not increasing related medications) (Δ = -1.6 ± SD 2.4, P = 0.05).
“Cardiometabolic risk, assessed via metabolic syndrome Z score, improved significantly for participants not increasing related medications (Δ = -1.6 ± SD 2.4, P = 0.05).”
Human trialfor participants not increasing related medicationstwo years post-intervention
Lifestyle modification program improves DAS28-CRP in participants who did not increase RA-related medications (mean change -1.0 ± SD 0.9).
“For the 12 participants who did not increase RA‐related medications, both DAS‐28 measures significantly improved compared to pre‐intervention values (DAS‐28‐CRP change: mean −1.0 ± SD 0.9; P = 0.002; Figure and DAS‐28‐ESR change: mean −1.3 ± SD 0.9; P = 0.0004).”
Human trialin participants who did not increase RA-related medications1.9 ± 0.5 yearsn = 12
What is lifestyle modification program linked with?
9
Studies link lifestyle modification program with 9 measures, among them mortality, type 2 diabetes and chronic disease.
Mortality
↓downin humans1↑upin humans1HR 0.66
2 studies
Lifestyle modification program raises the risk of mortality in humans (RR 1.28 (+28%)).
“When considering overall deaths during the study duration of included trials, the risk ratio describes a 28% relative increase in risk of death in the intervention group than in the control group (1.28 times as much probability).”
Human trialmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months)
European journal of gastroenterology & hepatology·
Type 2 diabetes
↓downin humans2
2 studies
Lifestyle modification program lowers the risk of type 2 diabetes in participants younger than 35.
“However, for participants younger than 35 (β=-0.42 [95%CI -0.83, -0.01]; p < 0.045), there was a significant decline in T2D risk scores in the intervention group comparing to the control group over time.”
Human trialin participants younger than 3518-month
Lifestyle modification program lowers the risk of chronic disease in humans.
“Lifestyle changes also promote cardiovascular and metabolic health, preserve bone and muscle mass, boost psychological well-being, and lower the chance of chronic disease.”
Lifestyle modification program lowers the risk of heart disease in humans.
“Early prevention through regular exercise, a heart-healthy diet, not smoking, limiting alcohol, managing stress, and maintaining a healthy weight can greatly reduce heart disease risk in women.”
Lifestyle modification program lowers the risk of distal symmetrical polyneuropathy in humans (increasing 5-year age intervals) (17.4% (95% CI 3.0, 29.3) lower OR).
“the odds ratio for DSPN in comparison with ILS with placebo was 17.4% (95% CI 3.0, 29.3) lower with increasing 5-year age intervals.”
Human trialincreasing 5-year age intervalsat DPPOS year 17
Lifestyle modification program lowers the risk of slow gait speed in humans (type 2 diabetes, overweight and obese) (adjusted OR 0.84 [0.71 to 0.99]).
“Individuals randomized to ILI had lower odds of slow gait speed (<0.8 m/s) compared to those randomized to DSE (adjusted OR [95% CI]: 0.84 [0.71 to 0.99]).”
Human trialtype 2 diabetes, overweight and obeseapproximately 11 years postrandomization and 1.5 years after the intervention was stoppedn = 3,783
Human trials report improved physical function with lifestyle programs, repeated by independent labs, but a trial reports increased mortality. Independent labs also find lower body weight and systolic blood pressure, although weight and physical activity results differ. Some papers have company-affiliated authors, and a paper declares company ties.
A six-month randomized trial in Arab adults found structured diet and exercise reduced biological age alongside metabolic markers.A six-month randomized trial in Arab adults found structured diet and exercise reduced biological age alongside metabolic markers.